In Brief: FDA's Drug Abuse Advisory Committee
This article was originally published in The Tan Sheet
Executive Summary
FDA's Drug Abuse Advisory Committee: Will meet Feb. 10 from 8:30 a.m. to 5 p.m. to discuss New Life Health Products' Quit brand silver acetate lozenges for smoking cessation. An open public hearing will take place from 8:30-9:30 a.m.; open committee discussion will begin at 9:30 a.m. and end at 10:30 a.m. for a closed session addressing trade secret information. On Feb. 11, the committee will discuss Carter-Wallace's prescription Soma (carisoprodol) tablets for muscle relaxation; under consideration will be a Drug Enforcement Agency petition regarding scheduling of the drug under the Controlled Substances Act...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning